Control of phosphorus accumulation in chronic renal insufficiency is crucial to the prevention
of secondary hyperparathyroidism and metastatic calcification. In early renal failure, calcitriol …

Phosphate binders that contain aluminum are frequently prescribed to treat
hyperphosphatemia in patients with chronic renal failure, but an accumulation of aluminum …

Hyperphosphataemia is prevalent among chronic renal failure and dialysis patients. It is
known to stimulate parathyroid hormone and suppress vitamin D3 production, thereby …

Secondary hyperparathyroidism and renal osteodystrophy are the consequences of
abnormal calcium, phosphate, and calcitriol metabolism ensuing from renal failure …

Aluminum-containing phosphate (Al-binders) employed to control serum phosphorus in
patients with chronic renal failure can be associated with the development of aluminum …

Aims: No conventional phosphate binder is entirely satisfactory for the treatment of
hyperphosphatemia in patients with end-stage renal disease (ESRD). Consequently, there …

Derangements of mineral metabolism occur during the early stages of chronic kidney
disease (CKD). Hyperphosphatemia develops in the majority of patients with ESRD and has …

A comparative study of long-term haemodialysis patients investigated the effects of calcium
acetate and calcium carbonate on concentrations of serum phosphate, calcium, and …

Hyperphosphatemia is a predictable consequence of chronic renal failure and is present in
most patients on dialysis. Traditionally, the risk associated with elevated serum phosphorus …

Calcium acetate has many characteristics of an ideal phosphorus binder. It is a readily
soluble salt that avidly binds phosphorus in vitro at pH 5 and above. One-dose/one-meal …